Desloratadine demonstrates dose proportionality in healthy adults after single doses

Clinical Pharmacokinetics

Volumn 41, Issue , 2002, Pages 1-6

  Gupta, Samir ^a   Banfield, Christopher ^a   Affrime, Melton ^a   Marco, Aliceann ^a   Cayen, Mitchell ^a   Herron, Jerry ^a   Padhi, Desmond ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; MALE; MIDDLE AGED;

EID: 0036074365     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241001-00001     Document Type: Article

References (5)

1. Pharmacokinetics: The dynamics of drug absorption, distribution, elimination
2. Second-generation antihistamines: The risk of ventricular arrhythmias
3. Clinical pharmacokinetics of phenytoin
4. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons